News
Keytruda is approved in China in combination with chemotherapy
Merck Inc., has announced that Keytruda, Merck’s anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA) in China in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus or gastroesophageal junction (GEJ).
This new indication was granted approval based on overall survival (OS) findings from the pivotal Phase III KEYNOTE-590 trial. Keytruda is now approved for eight indications across five different types of cancer in China.
Condition: Oesophageal Cancer + Gastro Junction
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.